These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17073517)

  • 1. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology and current treatment of neurodegenerative sphingolipidoses.
    Eckhardt M
    Neuromolecular Med; 2010 Dec; 12(4):362-82. PubMed ID: 20730629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
    Parenti G
    EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
    Shayman JA; Larsen SD
    J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for lysosomal storage disorders: developing insights.
    van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ
    Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in therapeutic approaches for lysosomal storage diseases.
    Urbanelli L; Magini A; Polchi A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):1-19. PubMed ID: 21073432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
    Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
    Parenti G; Andria G; Valenzano KJ
    Mol Ther; 2015 Jul; 23(7):1138-1148. PubMed ID: 25881001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of
    Sellin J; Schulze H; Paradis M; Gosejacob D; Papan C; Shevchenko A; Psathaki OE; Paululat A; Thielisch M; Sandhoff K; Hoch M
    Dis Model Mech; 2017 Jun; 10(6):737-750. PubMed ID: 28389479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement and enhancement therapies for lysosomal diseases.
    Desnick RJ
    J Inherit Metab Dis; 2004; 27(3):385-410. PubMed ID: 15190196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.